Barclays PLC Buys 61,317 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI)

Barclays PLC increased its position in Trevi Therapeutics, Inc. (NASDAQ:TRVI) by 180.8% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 95,232 shares of the company’s stock after acquiring an additional 61,317 shares during the quarter. Barclays PLC’s holdings in Trevi Therapeutics were worth $319,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in TRVI. Ally Bridge Group NY LLC purchased a new stake in shares of Trevi Therapeutics in the second quarter worth $4,395,000. Logos Global Management LP increased its stake in Trevi Therapeutics by 27.3% in the 2nd quarter. Logos Global Management LP now owns 2,800,000 shares of the company’s stock worth $8,344,000 after buying an additional 600,000 shares in the last quarter. GSA Capital Partners LLP bought a new stake in Trevi Therapeutics during the third quarter valued at about $409,000. Fred Alger Management LLC purchased a new position in shares of Trevi Therapeutics in the third quarter valued at about $256,000. Finally, State Street Corp boosted its stake in shares of Trevi Therapeutics by 5.9% in the third quarter. State Street Corp now owns 952,912 shares of the company’s stock worth $3,183,000 after acquiring an additional 53,051 shares during the period. Institutional investors own 95.76% of the company’s stock.

Trevi Therapeutics Trading Up 5.3 %

TRVI opened at $4.59 on Friday. The stock has a 50-day moving average of $3.31 and a 200 day moving average of $3.09. Trevi Therapeutics, Inc. has a 12 month low of $1.27 and a 12 month high of $4.68. The firm has a market cap of $352.81 million, a P/E ratio of -10.43 and a beta of 0.96.

Trevi Therapeutics (NASDAQ:TRVI) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.01). During the same quarter last year, the company earned ($0.08) earnings per share. On average, research analysts forecast that Trevi Therapeutics, Inc. will post -0.49 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts recently issued reports on the company. Leerink Partners began coverage on Trevi Therapeutics in a research note on Monday, September 9th. They set an “outperform” rating and a $7.00 target price on the stock. HC Wainwright boosted their target price on shares of Trevi Therapeutics from $6.00 to $7.50 and gave the stock a “buy” rating in a report on Thursday, December 12th. D. Boral Capital reaffirmed a “buy” rating and set a $21.00 target price on shares of Trevi Therapeutics in a research note on Thursday, December 12th. Needham & Company LLC reiterated a “buy” rating and issued a $8.00 price target on shares of Trevi Therapeutics in a research note on Thursday, December 12th. Finally, Leerink Partnrs upgraded Trevi Therapeutics to a “strong-buy” rating in a research report on Monday, September 9th. Eight investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Buy” and an average price target of $9.31.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.